FDA Approves WELIREG+LENVIMA for Advanced RCC, Bolstering Merck's Non-Keytruda Oncology Portfolio

What happened

The U.S. FDA approved Merck's WELIREG (belzutifan) in combination with LENVIMA (lenvatinib) for previously treated adult patients with advanced renal cell carcinoma with a clear cell component. This approval adds a new indication within Merck's oncology franchise, providing a differentiated combination option beyond Keytruda-centric regimens. The decision leverages Merck's existing commercial infrastructure for both drugs, potentially enhancing revenue from the kidney cancer market where LENVIMA already has a presence. While the specific patient population is relatively narrow, the approval reinforces Merck's strategy to build revenue pillars outside of Keytruda ahead of the 2028-2029 exclusivity cliff. The news is positive but incremental, unlikely to materially alter near-term financial projections given the size of the indication relative to Merck's $65 billion revenue base.

Implication

The approval of WELIREG plus LENVIMA adds another late-stage oncology asset to Merck's commercial portfolio, slightly reducing reliance on Keytruda for growth. However, the indication covers previously treated advanced renal cell carcinoma, a competitive space where multiple therapies exist, so revenue contribution is likely limited in the near term. The combination's success will depend on clinical differentiation, pricing, and adoption by oncologists, which may take time to materialize in reported sales. This event aligns with management's stated goal of building non-Keytruda revenue pillars, but it does not address the more significant near-term issues of Gardasil's China slump or the $2.5 billion 2026 headwind. For investors, the approval supports the bull case for Merck's long-term transition, but does not change the WAIT rating or the need to monitor Gardasil shipment resumption and headwind containment.

Thesis delta

The thesis remains unchanged: MRK is a transitioning pharma with a Keytruda concentration risk and a Gardasil China uncertainty. This approval slightly strengthens the bull scenario for non-Keytruda oncology growth, but the overall WAIT rating and $125 base-case implied value are maintained. No shift in conviction or entry/exit levels is warranted based on this news alone.